Attached files
| file | filename |
|---|---|
| EX-99.1 - 100218_ASB_FORM 8K_Q3-FY2010 EARNINGS PR_EX 99.1 - EKIMAS Corp | asbform8k_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 18, 2010 (February 17,
2010)
AdvanSource
Biomaterials Corporation
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-28034
|
04-3186647
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
229
Andover Street, Wilmington,
Massachusetts, 01887
|
|
(Address
of Principal Executive
Offices) (Zip
Code)
|
(978)
657-0075
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02. Results
of Operations and Financial Condition
On
February 17, 2010, AdvanSource Biomaterials Corporation issued a press release
announcing its financial results for the three and nine month periods ended
December 31, 2009. A copy of the press release is attached hereto as
Exhibit 99.1.
Item
7.01. Regulation
FD Disclosure
See Item
2.02 of this Form 8-K.
Item
9.01. Financial
Statements and Exhibits
(d)
Exhibits
Exhibit
No. Description
|
|
99.1
|
Press
Release of AdvanSource Biomaterials Corporation dated February 17,
2010.
|
The
information included in this Current Report on Form 8-K (including the exhibit
attached hereto) is being furnished under Item 2.02, “Results of Operations and
Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01
“Financial Statements and Exhibits” of Form 8-K. As such, the
information (including the exhibit) herein shall not be deemed to be “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be incorporated by reference into a filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such a filing. This Current Report
(including the exhibit attached hereto) will not be deemed an admission as to
the materiality of any information required to be disclosed solely to satisfy
the requirements of Regulation FD.
|
|
SIGNATURES
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ADVANSOURCE
BIOMATERIALS CORPORATION
By: /s/ Michael F.
Adams____
Michael
F. Adams
President
& CEO
Dated: February
18, 2010
|
|
EXHIBIT
INDEX
|
Exhibit
No. Description
|
|
99.1
|
Press
Release of AdvanSource Biomaterials Corporation dated February 17,
2010.
|